Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.

Jacob KmentDaniel NewstedStephanie YoungMichael C VermeulenBrian J LaightPeter A GreerYan LanAndrew W B Craig

Published in: British journal of cancer (2024)

Our preclinical studies of BA in advanced ovarian cancer models support further testing of BA as an improved immunotherapy option for patients with advanced ovarian cancer.

Keyphrases

nk cells
cell therapy
regulatory t cells
transforming growth factor
stem cells
bone marrow
replacement therapy